210 related articles for article (PubMed ID: 38439005)
1. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.
Fang G; Liu S; Liu B
BMC Gastroenterol; 2024 Mar; 24(1):94. PubMed ID: 38439005
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Zacharias HD; Kamel F; Tan J; Kimer N; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011585. PubMed ID: 37467180
[TBL] [Abstract][Full Text] [Related]
4. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis.
Ahmed Z; Hassan M; Arif SF; Aziz M; Iqbal U; Nawaz A; Farooq U; Smith WL; Badal J; Renno A; Javaid T; Nawras A; Saab S
J Gastrointestin Liver Dis; 2023 Apr; 32(1):70-76. PubMed ID: 37004220
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy.
Kimer N; Krag A; Møller S; Bendtsen F; Gluud LL
Aliment Pharmacol Ther; 2014 Jul; 40(2):123-32. PubMed ID: 24849268
[TBL] [Abstract][Full Text] [Related]
7. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.
Han X; Luo Z; Wang W; Zheng P; Li T; Mei Z; Wang J
Front Pharmacol; 2021; 12():696065. PubMed ID: 34690751
[No Abstract] [Full Text] [Related]
9. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
10. Minimal hepatic encephalopathy in cirrhosis- how long to treat?
Goyal O; Sidhu SS; Kishore H
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Probiotics and Symbiotics on Risk Factors for Hepatic Encephalopathy: A Systematic Review.
Viramontes Hörner D; Avery A; Stow R
J Clin Gastroenterol; 2017 Apr; 51(4):312-323. PubMed ID: 28059938
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.
Fu J; Gao Y; Shi L
PLoS One; 2022; 17(4):e0267647. PubMed ID: 35471992
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: A systematic review and meta-analysis.
Wibawa IDN; Mariadi IK; Shalim CP; Sindhughosa DA
Clin Exp Hepatol; 2023 Jun; 9(2):146-153. PubMed ID: 37502435
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Cai XJ; Wang L; Hu CM
J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
[TBL] [Abstract][Full Text] [Related]
15. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
16. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.
Moran S; López-Sánchez M; Milke-García MDP; Rodríguez-Leal G
World J Gastroenterol; 2021 Jun; 27(22):3050-3063. PubMed ID: 34168407
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Variable Treatment Options in the Prevention of Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
Hammd M; Elghezewi A; Abdulhadi A; Alabid A; Alabid A; Badi Y; Kamal I; Hesham Gamal M; Mohamed Fisal K; Mujtaba M; Sherif A; Frandah W
Cureus; 2024 Jan; 16(1):e53341. PubMed ID: 38435950
[TBL] [Abstract][Full Text] [Related]
18. Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy.
Mangas-Losada A; García-García R; Leone P; Ballester MP; Cabrera-Pastor A; Urios A; Gallego JJ; Martínez-Pretel JJ; Giménez-Garzó C; Revert F; Escudero-García D; Tosca J; Ríos MP; Montón C; Durbán L; Aparicio L; Montoliu C; Felipo V
J Transl Med; 2019 Aug; 17(1):293. PubMed ID: 31462286
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
Bajaj JS; Pinkerton SD; Sanyal AJ; Heuman DM
Hepatology; 2012 Apr; 55(4):1164-71. PubMed ID: 22135042
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
Dhiman RK; Thumburu KK; Verma N; Chopra M; Rathi S; Dutta U; Singal AK; Taneja S; Duseja A; Singh M
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):800-812.e25. PubMed ID: 31476436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
